Landmark trial shows aspirin does not prevent cognitive decline in healthy elderly PRESS RELEASE: 1st April 2020 – Melbourne Researchers at Monash University and the Berman Center for Outcomes and Clinical Research in the US, have found that daily aspirin does not reduce the risk of Alzheimer’s disease, mild cognitive impairment, or cognitive decline…
Details
Impact of ASPREE trial on public health recognised. ASPREE researchers acknowledge the contribution of participants, GPs and fellow team members to the world-first trial. We are pleased to share details and photos of three Australian research awards recently won by the ASPREE study for its significance to public health. Monash University Dean’s Award…
Details
Landmark study to assess long-term health risks and benefits of prior aspirin use in elderly Landmark ASPREE study extended for five years to track study participants for long-term health outcomes after discontinuing aspirin. ASPREE-XT will investigate the long-term health in people over 70 (65 years in the US) following conclusion of ASPREE (low dose…
Details
Thanks to the American College of Cardiology, we are pleased to share this physician-penned article on the importance of the ASPREE study and the implications that study findings have on healthcare of older people around the world. The ASPREE Aftermath: A Geriatric Perspective on the Role of Aspirin in Older Adults Oct 11,…
Details
Welcome to our US NCI colleagues ASPREE investigators welcomed members from the National Cancer Institute (NCI) to the School of Public Health and Preventive Medicine, Monash University late last month. The NCI, a branch of the National Institutes of Health in the USA, funds ACES, the ASPREE Cancer Endpoints Study to better understand the…
Details
Daily low-dose aspirin doesn’t reduce heart-attack risk in healthy people from shutterstock.com John McNeil, Monash University Taking low-dose aspirin daily doesn’t preserve good health or delay the onset of disability or dementia in healthy older people. This was one finding from our seven-year study that included more than 19,000 older people from Australia and the…
Details
Head Office Moves Across Road The ASPREE National Co-ordinating Centre recently moved to the Alfred Centre, located across the road from our old office. After seven years on the ground floor, the Melbourne team is being treated to impressive views of Fawkner Park! It is important to note that our email and phone details have not changed and…
DetailsASPREE Ballarat team moves to new site in Wendouree Last month ASPREE Study Co-ordinators Sussan Conway and Theresa Grice relocated to their new office at the Ballarat Allergy Clinic, 1011 Howitt Street, Wendouree. ASPREE sincerely thanks Dr Harry Zehnwirth and his team for the warm welcome to the building. Telephone contact details for Sussan and…
Details
US ASPREE collaborators and NCI guests visit Melbourne. Earlier this month we welcomed our US research collaborators from the Berman Center for Outcomes and Clinical Research, along with guests from the National Cancer Institute (NCI), to discuss the progress and future of the ASPREE trial and sub-studies. The Berman Center for Outcomes and Clinical Research co-ordinates…
Details© 2019 All Rights Reserved. • Monash University, Department of Epidemiology and Preventive Medicine | Disclaimer & Privacy